Cargando…

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

OBJECTIVE: The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS: A total...

Descripción completa

Detalles Bibliográficos
Autores principales:	Preiss, David, Zetterstrand, Sofia, McMurray, John J.V., Östergren, Jan, Michelson, Eric L., Granger, Christopher B., Yusuf, Salim, Swedberg, Karl, Pfeffer, Marc A., Gerstein, Hertzel C., Sattar, Naveed
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671104/ https://www.ncbi.nlm.nih.gov/pubmed/19196892 http://dx.doi.org/10.2337/dc08-1709

Ejemplares similares

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
por: Dubé, Marie‐Pierre, et al.
Publicado: (2022)

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2008)

Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
por: Kassem, Imad, et al.
Publicado: (2020)

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
por: Abdul-Rahim, Azmil H., et al.
Publicado: (2017)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
por: Ravangard, Ramin, et al.
Publicado: (2023)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study
por: Welsh, Paul, et al.
Publicado: (2019)

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2020)

Talking to patients with heart failure about end of life
por: Campbell, Ross T., et al.
Publicado: (2018)

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study
por: Welsh, Paul, et al.
Publicado: (2017)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest
por: Aune, Emma, et al.
Publicado: (2022)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
por: Packer, Milton, et al.
Publicado: (2021)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
por: Tardif, Jean‐Claude, et al.
Publicado: (2022)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2019)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals
por: Farooqi, Mohammed A. M., et al.
Publicado: (2020)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it
por: Ahmad, Faheem A., et al.
Publicado: (2019)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
por: Rørth, Rasmus, et al.
Publicado: (2018)

Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes
por: Wolsk, Emil, et al.
Publicado: (2022)

The obesity paradox in men with coronary heart disease and heart failure: The role of muscle mass and leptin()()()
por: Wannamethee, S. Goya, et al.
Publicado: (2014)

A Case of Significant Improvement of Heart Failure With Reduced Ejection Fraction With a Small Dose of Candesartan in a Hemodialysis Patient With Hypertensive Heart Disease and Nephrosclerosis
por: Harada, Haruhito, et al.
Publicado: (2023)

Telemedicine and its impact on heart failure morbidity and mortality
por: Tan, M.M., et al.
Publicado: (2022)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?
por: Stewart, Simon, et al.
Publicado: (2019)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jtbpnurbjrcg32tdkqjc1hsodg